Compare Futu Holdings Ltd (FUTU) vs McKesson Corporation (MCK) Price & Performance

Futu Holdings (FUTU) trades at $108.76, down 3.93% on the day amid a bearish technical signal, though it remains above key support near $107. The company reported strong Q2 2026 earnings with a beat on EPS of $3.33 versus $2.98 expected, continuing robust revenue growth that reached $22.85 billion in 2025. However, a securities class action lawsuit deadline on August 25, 2026, adds near-term uncertainty.

The outlook is mixed: solid fundamentals with a low P/E of 10.95 and high net margin of 42.92% support upside potential, but technical weakness and legal overhangs pose risks. Analyst consensus is bullish with a 33.7% upside target, yet investors must weigh growth against litigation and market sentiment pressures.

McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.

Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.